FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to a composition containing a pharmaceutically acceptable carrier, at least one compound of the avermectins family and at least one non-steroidal anti-inflammatory agent.
EFFECT: present invention also provides such a composition for use in treating and/or preventing rosacea.
7 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF AVERMECTINE OR MILBEMYCIN WITH ADRENERGIC RECEPTORS FOR TREATING OR PREVENTING DERMATOLOGICAL DISEASES | 2010 |
|
RU2531087C2 |
| COMBINATION OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND NON-STEROID ANTI-INFLAMMATORY DRUG FOR TREATING OR PREVENTING INFLAMMATORY SKIN INJURY | 2010 |
|
RU2532388C2 |
| COMPOUND OF AVERMECTIN FAMILY OR OF MILBEMYCIN FAMILY FOR TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS | 2014 |
|
RU2669942C1 |
| AVERMECTIN OR MILBEMYCIN FAMILY COMPOUND FOR TREATMENT AND/OR PREVENTION OF ADOPIC DERMATITIS | 2014 |
|
RU2792693C2 |
| TREATMENT OF INFLAMMATORY DAMAGES IN CASE OF ROSAZEA USING IVERMECTIN | 2014 |
|
RU2633481C2 |
| PAPULOPUSTULAR ROSACEA TREATMENT BY IVERMECTIN | 2014 |
|
RU2633076C2 |
| METHOD OF TREATMENT OF ROSACEA | 2020 |
|
RU2811956C2 |
| METHOD FOR COMBINATION THERAPY OF ROSACEA | 2021 |
|
RU2806053C2 |
| METHOD OF COMPLEX EXTRINSIC FOR PATIENTS WITH ERITHEMATOUS PAPULAR ROSACEA | 2017 |
|
RU2645932C1 |
| METHOD OF LOCAL TREATMENT OF FACIAL PAPULOPUSTULAR DERMATOSES | 2022 |
|
RU2790768C1 |
